布地奈德联合干扰素α2b雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估  

Evaluation of the Efficacy and Safety of Budesonide Combined with Interferonα2b Nebulization in the Treatment of Infantile Bronchopneumonia

作　　者：袁斌 蔡金标[1] 王娟 吕亚莉[1] 李晓会 YUAN Bin;CAI Jinbiao;WANG Juan(General Hospital of Wanbei Coal and Electric Power Group,Anhui Wanbei 234000,China)

机构地区：[1]皖北煤电集团总医院儿内科,安徽皖北234000

出　　处：《河北医学》2024年第10期1739-1745,共7页Hebei Medicine

基　　金：2021年安徽省卫生健康委科研项目,(编号:AHWJ2021b104)。

摘　　要：目的:探究布地奈德联合干扰素α2b雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估。方法:纳入我院在2021年9月至2023年7月收治的102例支气管肺炎婴幼儿,按照随机数字表法将其分为常规组(给予常规对症治疗+布地奈德雾化吸入)与联合组(在常规组基础上联合干扰素α2b雾化吸入),各51例。对比两组患儿临床疗效、症状(咳嗽、喘憋、哮鸣音、三凹征)好转时间、治疗前后血气指标[氧合指数、氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))]、T淋巴细胞指标[CD3^(+)CD4^(+)、CD3^(+)CD8^(+)、CD3-CD19^(+)]变化,对比药物不良反应。结果:联合组总有效率(98.40%)高于常规组(86.27%)(P<0.05);联合组症状好转时间均短于常规组(P<0.05);治疗前,2组血清指标差异无统计学意义(P>0.05),治疗后,2组患儿氧合指数与PaO_(2)均升高(P<0.05),PaCO_(2)下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);治疗前,2组T淋巴细胞指标差异无统计学意义(P>0.05),治疗后,2组患儿CD3^(+)CD4^(+)、CD3^(+)CD8^(+)均上升(P<0.05),CD3-CD19^(+)下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);治疗前,2组外周血炎症指标差异无统计学意义(P>0.05),治疗后,2组患儿外周血炎症指标(IL-6、TNF-α、CRP)均下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);联合组药物不良反应合计发生率(7.84%)与常规组(5.88%)差异无统计学意义(P>0.05)。结论:布地奈德联合干扰素α2b雾化吸入治疗利于改善支气管肺炎婴幼儿临床症状、肺功能及免疫炎症反应,提升疗效,安全性高,值得应用。Objective:To evaluate the efficacy and safety of budesonide combined with interferonα2b nebulization in the treatment of infantile bronchopneumonia.Methods:A total of 102 infants and young children with bronchopneumonia admitted to our hospital from 2021.09 to 2023.07 were enrolled.According to the random number table method,they were divided into the conventional group(conventional symptomatic treatment^(+)budesonide atomization inhalation)and combined group(combined with interferonα2b atomization inhalation on the basis of the conventional group),with 51 cases in each group.The clinical efficacy,improvement time of symptoms(cough,wheezing,wheezing rale,three concave signs),blood gas indexes[oxygenation index,partial pressure of oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2))],T lymphocyte indicators(CD3^(+)CD4^(+),CD3^(+)CD8^(+),CD3-CD19+)and peripheral blood inflammation indexes[Interleukin-6(IL-6),tumor necrosis factorα(TNF-α),C-reactive protein(CRP)]before and after treatment were compared between the two groups,and the adverse drug reactions were compared.Results:The total effective rate of the combined group(98.40%)was higher than that of the conventional group(86.27%)((P<0.05).The improvement time of symptoms in the combined group was shorter than that in the conventional group(P<0.05).Before treatment,there were no statistical differences in serum indexes between groups(P>0.05).After treatment,the oxygenation index and PaO_(2)in the two groups were increased(P<0.05)while the PaCO_(2)was decreased(P<0.05),and the differences before and after treatment in the combined group were higher(P<0.05).No statistical differences were shown in T lymphocyte indexes between groups before treatment(P>0.05).After treatment,CD3^(+)CD4^(+)and CD3^(+)CD8^(+)in both groups of children were risen(P<0.05)while CD3-CD19++was declined(P<0.05),and the differences before and after treatment were higher in the combined group than those in the conventional group(P<0.05).Before treatment,there were no statistical di

关 键 词：支气管肺炎 痉挛性咳嗽 布地奈德 干扰素Α2B 糖皮质激素 

分 类 号：R725.6[医药卫生—儿科]